Next Article in Journal
The Discovery of Novel Antimicrobial Agents through the Application of Isocyanide-Based Multicomponent Reactions
Previous Article in Journal
Systemic Antibiotics and Chlorhexidine Associated with Periodontal Therapy: Microbiological Effect on Intraoral Surfaces and Saliva
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Antibiotics
Volume 12
Issue 5
10.3390/antibiotics12050848
antibiotics-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Voriconazole Admixed with PMMA—Impact on Mechanical Properties and Efficacy

by
Barbara Krampitz
1,
Julia Steiner
2,
Andrej Trampuz
3 and
Klaus-Dieter Kühn
2,*
1
Medical Training and Science, Heraeus Medical GmhH, Hamburger Allee 50, 60486 Frankfurt, Germany
2
University Hospital for Orthopaedics and Traumatology, Medical University of Graz, 8036 Graz, Austria
3
Infectious Diseases, Center for Musculoskeletal Surgery, Charité, Universitätsmedizin Berlin, 10117 Berlin, Germany
*
Author to whom correspondence should be addressed.
Antibiotics 2023, 12(5), 848; https://doi.org/10.3390/antibiotics12050848
Submission received: 14 March 2023 / Revised: 25 April 2023 / Accepted: 27 April 2023 / Published: 4 May 2023
(This article belongs to the Special Issue Effect of Antimicrobials on Fungal Biofilms)
Browse Figures
Review Reports Versions Notes

Abstract

:
Background: There are currently no recommendations to direct the optimal diagnosis and treatment of fungal osteoarticular infections, including prosthetic joint infections and osteomyelitis. Active agents (fluconazole; amphotericin B) are regularly applied per os or intravenously. Other drugs such as voriconazole are used less frequently, especially locally. Voriconazole is less toxic and has promising results. Local antifungal medication during primary surgical treatment has been investigated by implanting an impregnated PMMA cement spacer using intra-articular powder or by daily intra-articular lavage. The admixed dosages are rarely based on characteristic values and microbiological and mechanical data. The purpose of this in vitro study is to investigate the mechanical stability and efficacy of antifungal-admixed PMMA with admixed voriconazole at low and high concentrations. Methods: Mechanical properties (ISO 5833 and DIN 53435) as well as efficacy with inhibition zone tests with two Candida spp. were investigated. We tested three separate cement bodies at each measuring time (n = 3) Results: Mixing high dosages of voriconazole causes white specks on inhomogeneous cement surfaces. ISO compression, ISO bending, and DIN impact were significantly reduced, and ISO bending modulus increased. There was a high efficacy against C. albicans with low and high voriconazole concentrations. Against C. glabrata, a high concentration of voriconazole was significantly more efficient than a dose at a low concentration. Conclusions: Mixing voriconazole powder with PMMA (Polymethylmethacrylate) powder homogeneously is not easy because of the high amount of dry voriconazole in the powder formulation. Adding voriconazole (a powder for infusion solutions) has a high impact on its mechanical properties. Efficacy is already good at low concentrations.

1. Introduction

Fungal periprosthetic joint infections (FPJIs) are considered a rarity [1,2,3]. These complications have a low incidence among PJIs [3,4,5,6]. Fungal infections are generally associated with bacteria. They affect patients with decreased immunity, especially during revisions [6,7] with polymicrobial infections [8,9]. They are most frequently identified as yeasts (especially Candida spp.), which are difficult to treat [10,11]. The antifungal agents most frequently admixed with PMMA are voriconazole [12], amphotericin B [13], fluconazole [14], and echinocandins [15]. The admixture of anti-infectives is a routine procedure for spacers and bone cement for fixation [16]. Endo Klinik uses antifungal agents in PMMA for one-stage septic fungal revisions. To combat fungal infection, attempting to use antifungal-loaded bone cement (ALFBC) in a spacer is promising during a recommended two-stage procedure [17,18]. The preparation and use of the drugs under sterile conditions is a prerequisite for admixture with PMMA. The use of pharmaceutical formulations requires a high amount of sterile powder with a small amount of pure voriconazole. This might have a significant influence on the mechanical properties, although small voriconazole dosages are admixed to PMMA [11,12,13]. Voriconazole has been selected because it is less nephrotoxic and has fewer side effects than amphotericin B [6,7,12]. The dose recommendations for voriconazole range from 200 to 600 mg/40 g PMMA cement [15,16] (Consensus Recommendations 2013, Pocket Guide). There are missing data in the literature concerning the ISO and DIN mechanical tests of voriconazole in the PMMA (ISO 5833:2002, DIN 53435:1983) [19,20].
To find suitable recommendations and optimized findings, the present study focuses upon the following questions: To what extent do admixed antifungals interfere with the mechanical stability of bone cement? Does voriconazole eluted from PMMA inhibit the growth of Candida albicans and Candida glabrata strongly in inhibition zone assays?

2. Results

The mixture of PMMA cement with a low dosage (200 mg) of voriconazole (44 g powder) was dry (Figure 1a,b). The production, especially with the high dosage of voriconazole, was distinctly dry with white specks. It was difficult to obtain a homogenous mixture.
Voriconazole was formed with the admixture of 10.5 g to the previously mentioned exception outside the ISO standard. The admixture of 3.5 g voriconazole also showed a reduced compressive strength but, at 74.4 MPa, it was still above the standard specifications. The vertical axis here describes the PMMA cement Palacos R + G used as a reference value (Figure 2).

2.1. ISO Bending Strength

A significant reduction in the bending strength could be observed after voriconazole was added to PMMA. Low dosages just met the ISO specification (50 MPa), and high dosages were well below it at 37 MPa (Figure 3).

2.2. ISO Bending Modulus

Admixing voriconazole with PMMA increased the ISO bending modulus with low dosages (2983 MPa), as well as with high concentrations (3040 MPa), in comparison to the reference (2769 MPa). The higher the dose of voriconazole in PMMA, the higher the bending modulus Figure 4.

2.3. DIN Impact Strength (Dynstat)

Dynstat impact strength was significantly reduced after the addition of voriconazole. In comparison to the reference (3.14 kJ/m2), the impact strength was made 43% lower by adding low dosages to PMMA (1.78 kJ/m2) and 64% after admixing high voriconazole concentrations (1.12 kJ/m2). The higher the voriconazole concentration in PMMA, the lowe r the DIN impact strength (Figure 5)

2.4. Inhibition Zone Tests

It was visible that voriconazole was active against Candida albicans and Candida glabrata over a period of 6 weeks after it was added to PMMA. The efficacy against Candida albicans was good at low and high dosages in PMMA. High voriconazole concentrations showed a better efficacy against Candida albicans up to day 15 compared with low dosages of voriconazole. (Figure 6. Low concentrations of voriconazole in PMMA against Candida glabrata were distinctly weaker than high dosages of voriconazole. Low concentrations of voriconazole showed a constant low efficacy against Candida glabrata over 42 d (Figure 7).

3. Materials and Methods

3.1. Materials

Palacos R + G was used as a PMMA reference. Appropriate amounts of voriconazole were added to Palacos R + G powder (Table 1). The voriconazole used was in the form of 200 mg powder (Rotexmedica), which was added manually to PMMA powder in low (200 mg) and high (600 mg) voriconazole dosages. The PMMA quantity of low dosages of voriconazole was 44 g and the quantity of high dosages was 51 g. The homogeneity of the powder and the set cement was visually detected.
Voriconazole, manufactured as a sterile powder for a solution for infusion, was delivered as a white-to-cream-colored lyophilized powder Hydroxy-Propyl Beta-Dex (HPBCD, Cyclodextrin) and was added within a range of 0.81–0.99 as a pharmaceutical additive in a vial. The holder of the marketing authorization is Xellia Pharmaceuticals, Kopenhagen, Denmark (Data Safety Data Sheet, source: URL http://www.cymitquimica.com/uploads/products/45/pdf/1329709-msds.pdf, accessed on 25 June 2020).

3.2. Methods

3.2.1. Mechanical Testing

Compression strength was determined in MPa according to ISO 5833. A testing overview is summarized in Table 2. Cylindrical specimens with a diameter of 6 mm and a height of 12 mm were loaded with a constant crosshead speed of 19.8–25.4 mm/min. The tests were run at 23 ± 1 °C with dry specimens prepared 24 h before testing. According to ISO 5833 (2002) statistics, we calculated the average strength and standard deviation for 6 cylinders [19].
For ISO 5833 bending strength and bending modulus, rectangular specimens were used (3.3 × 75.0 × 10.0 mm). They were loaded with a constant crosshead speed of 5 mm/min. The tests were run at 23 ± 1 °C with dry specimens prepared 24 h before testing. The four-point test rig had 60 mm between the outer loading points and 20 mm between the inner loading points. The tests were continued until failure, and the maximum force was used to calculate the bending strength. The bending modulus was calculated from the difference between the deflections under loads of 15 N and 50 N [19].
According to ISO 5833 statistics, we calculated the average and the standard deviation of the values for six test specimens in MPa [19].
To determine the impact strength according to DIN 53435, 3 × 10 × 15 mm specimens were produced in special plates. The specimens were tested after storage for at least 12 h under standard climatic conditions using the appropriate impact direction (consumption of at least 10%, at most 80%, of the maximum impact by the test specimens). The test specimens needed to be placed exactly vertical in the test device. Then, the pendulum could be adjusted to 90° the height of the drop. The impact used is shown by the maximum indicator. Impact strength is often used as a parameter to describe the properties of materials being exposed to high and fast impacts, such as plastic materials for cars. Impact strength is a measure of the energy required to cause a material to fracture when struck by a sudden blow. According to DIN 53435 statistics, we calculated the average and the standard deviation of the values for 10 test specimens in kJ/m2 [20].

3.2.2. Inhibition Zone Testing

For testing the efficacy of added voriconazole eluted from PMMA, we used the inhibition zone test. We used cylindric cement bodies of 25 mm diameter ×10 mm height. One cement body per dosage was incubated in vitro in a buffer solution at room temperature.
The voriconazole containing cement bodies were incubated in PBS buffer at room temperature. The measuring times were 1 h, 24 h, 7 d, 14 d, 28 d, and 42 d. After these measuring points as described before, a portion of this solution (60 µL = here called eluate) was taken and pipetted onto previously grown Candida colonies on Soubaroud plates (for 24 h at 37 °C). We tested 3 separate cement bodies at each measuring time (n = 3).The inhibition zone’s diameter was measured against Candida albicans and Candida glabrata. We calculated the average and the standard deviation of the zones of inhibition in mm (Figure 8a,b).

4. Discussion

We found that the mechanical stability (ISO compression, ISO bending, DIN impact strength) (Table 2) of bone cement decreases when voriconazole was admixed with one exception, the bending modulus, which increased.
Studies on the mechanical stability of voriconazole containing PMMA cement have been limited to compressive strength [2,12,21,22]. Reduced compressive strength was measured by Czuban et al. 2019 [22] after antifungal elution. According to this Czuban study, the reason for reduced compressive strength might be Gentamicin with Palacos R + G (industrially premixed with 0.5 g gentamicin), which was recognized as a poragen and was found to boost antifungal release [22,23]. Compressive strength slightly decreased, as the obtained values were above the level of the strength recommended for the implant fixation. Miller et al. (2013) [12] were the first to investigate compressive strength in antifungal-loaded Simplex P bone cement. The 600 mg voriconazole formulation was less than half of the required strength by the first day of elution. Miller et al. also noticed that the strength of both 300 mg and 600 mg was lower than recommended at the time for fixation.
According to our observations, the reduced compressive strength does not depend on the active ingredient release, but on the excessive powder quantity by admixing of voriconazole in PMMA (Recommendation: max 10% of the PMMA powder; actually, a low dose adds 7.9%, a high dose adds 26% of powder with voriconazole).
In ISO tests and after storage in a liquid medium, the question generally arises as to whether the ISO method can still be fulfilled and thus whether the limit values can be complied with. Our results show that high dosages of voriconazole mean 10.5 g powder (600 mg pure voriconazole) decreases the ISO slightly to 68 MPa compared to the ISO standard (70 MPa).
We did not find that ISO bending, DIN impact strength, and bending modulus were tested in other studies.
The bending strength of the high concentration of 600 mg voriconazole was significantly reduced to 37 MPa, with a limit of 50 MPa according to ISO. This means that the bending strength according to ISO is 26% below the limit value.
For DIN Impact strength, we found a significant reduction with low and high dosages of low voriconazole. It is well known that admixing [24,25] of antibioticswith PMMA influences mechanical properties. The more additional substance is added, the more it reduces the mechanical strength. The rule of thumb to add a maximum of 10% powder to the PMMA is confusing. The logic behind it is that the amount of active ingredient of voriconazole is not identical to the amount of powder. The commercial powder contains excipients (e.g., cyclodextrin) of up to 93.5%. If 200 mg of voriconazole is added, 3.5 g of a foreign substance is added to the PMMA (equal to plus 7.95%). If 600 mg of voriconazole is added, 10.5 g of the voriconazole powder substance is added, 26% instead of max. 10% is added to PMMA. From our point of view, the reduced mechanical solidity is only because it is not a pure substance but a powder for infusion. In addition to the active ingredient, they contain many other pharmaceutical excipients. Therefore, when adding voriconazole to PMMA cement, it is always necessary to carefully check which type of pharmaceutical formulation is used.
The mechanical properties of PMMA plus high/low voriconazole are reduced and, at the same time, PMMA plus low voriconazole is within the acceptable range of the ISO.
The manual admixture of high voriconazole dosages of 10.5 g (voriconazole powder for infusion contains 600 mg active ingredient) with PMMA increased the powder content to more than 10% of the total amount of manually prepared AFLBC. This significantly reduced the mechanical strength [26]. The most sensitive influence after admixing drugs with PMMA was the bending and impact strength [27].
The mechanical performance of PMMA cements is influenced by various parameters; as such, a larger amount of the substance increases the hydrophilicity [28,29]. The parameters are the composition of the cement, the porosity, and the preparation of the cement. The addition of radio opacifiers and antibiotics to bone cement slightly decreases its mechanical strength [26,30,31,32], as do antifungals such as voriconazole.
In addition, PMMA spacers have a relatively high mass and diameter, which are significantly more mechanically stable than thin cement layers for the fixation of the prosthesis. The DIN impact strength represents a stronger indication of mechanical sensitivity. Deviations from the standard spacers are investigated in solutions to approximate the in vivo situation.
Selected examples show that the results are currently not comparable (Table 3).
However, EUCAST susceptibility breakpoints have not been established due to a paucity of efficacy data. Due to the small number of patients with C. glabrata infections treated with voriconazole, clinical efficacy and pharmacokinetic (PK)–MIC data might help describe exposure [32].
In our in vitro study, voriconazole showed a very good effect against Candida albicans with inhibition peaks around 30 mm after a duration of 6 weeks. Against Candida glabrata, the inhibitory effect is borderline, especially when 300 mg was admixed. When admixing 600 mg, inhibition zones of 40 mm diameter were observed after 6 weeks, and there was thus a good inhibitory effect here.
WHO’s Fungal Priority List (FPPL) classifies C. albicans in the highest category as a Critical Priority Group and C. clabrata (Nakaseomyces glabrata) as a High-Priority Group. In 2022, the WHO FPPL made the first global effort to systematically prioritize fungal pathogens, considering their unmet R&D needs and perceived importance to public health [33]. Voriconazole is an essential medicine according to the WHO.

4.1. Considerations for Local Application of Voriconazole in PMMA

The local clinical application of voriconazole in spacers is intended to provide high-dose adjuvant antifungal therapy by releasing active substances at the site of infection. The dosage recommendations (0.3–0.6 g) [34] are rarely based on characteristic values, microbiological, or mechanical data. High doses of voriconazole are required to effectively control biofilm [13].
Sterile voriconazole is only available as a powder solution for infusion. These commercially available preparations contain a lot of pharmaceutical excipients in powder form but are low in the active ingredient voriconazole. Mixing high dosages of voriconazole causes white specks on the inhomogeneous cement surface. The visibility of the specks is particularly clear due to the green-colored cement, especially in high-dosage voriconazole (600 mg). Already, the mixing of the two powders (PMMA and voriconazole) reveals specks in an inhomogeneous mixture. It is recognizable at an early stage whether a mortar must be used for homogenization.
Studies do not normally specify the composition of voriconazole preparations, only the amount of the active ingredient in pure form is mentioned.
In the present study, voriconazole from the company Rotexmedica was used. Importantly, 200 mg and 600 mg of voriconazole (active ingredient) were provided in a powder for the infusion dosage form, with a total weight of 3.5 g and 10.5 g, respectively. The excipients unfavorably influence the mechanical strengths; moreover, they improve the release and efficacy. The efficacy of voriconazole is good even at low dosages.
The good efficacy, because poragen is included, is a disadvantage for the mechanical properties [28].
The exact compositions of the cement are often not specified.

4.2. Miscibility of Antifungals and Orthopedic Cement

Adjuvant therapy with local antimycotics in PMMA cement is becoming increasingly important [2]. Currently, no bone cement with admixed antimycotics is available commercially as an approved medical device. The surgeon must admix the substances manually as needed. The documented findings might support preparations of AFLBC onsite.
While mixing an AFLBC with voriconazole (as a powder for infusion), dose-dependent observations were witnessed.
First, the color and consistency changed when the two powders were mixed (PMMA and voriconazole). Depending on the dose of voriconazole added, the green cement powder used as a reference in our study became lighter in color. In addition, the miscibility became more difficult with increasing doses (see Figure 1b). This might be attributed to the lipophilicity of voriconazole [22,35].
The second observation was visible specks in the reference used. The green coloration made the contrast more visible. While mixing white voriconazole powder in white PMMA cement powder, inhomogeneities were hardly visible and may have appeared due to reduced hydrophilicity. This effect was particularly predominant at high dosages (600 mg in 10.5 g) of voriconazole (Figure 1d). To produce a homogeneous mixture, mortar is needed.
In the case of commercially available voriconazole formulations, the excipient ß-cyclodextrin accounts for 94% of the total weight.
Cyclodextrin is thus the limiting factor in voriconazole to increase the dosage. In addition, it impairs miscibility with orthopedic cement. The cement agglutinates or becomes crumbly. At the same time, ß-cyclodextrin improves the bioavailability of voriconazole.
Practical recommendations can be deduced to receive a homogenous cement dough:
Cool highly viscous orthopedic bone cement (powder and liquid monomer);
Use low viscosity orthopedic bone cement (especially for the spacer);
For spacer production extracorporeally, use a little more liquid monomer to obtain a homogeneous mixture/dough (p.r.n./if needed).
Cave: If more monomer liquid is used, the setting temperature in the residual monomer may increase.
Alternatively, only if sterile powdery antibiotics are not suitable or available for the admixture with PMMA, liquid antibiotics may be used as an effective alternative. If the admixture of liquid AB is inevitable, the admixture of liquid AB with the liquid monomer should be considered, followed by blending with the polymer powder. We discourage admixing liquid AB with PMMA powder or cement dough with low viscosity [36].
Studies have shown that the admixture of liquids with PMMA significantly reduces the mechanical properties and significantly deteriorates the effectiveness.

4.3. Future Considerations about Antifungal Dosage

It is questionable whether sterile voriconazole as a pure substance, if available, would show a better release from PMMA than voriconazole combined with pharmaceutical excipients. Of course, mechanical stability would hardly be affected by small amounts of voriconazole.
The release-supporting effect of currently available preparations for infusion could be omitted.
PMMA’s function as a drug carrier is currently being investigated. The incidence of fungal PJI is rising (Consensus 2018) [34,37,38] and has a much higher failure rate than bacterial infections, with eradication rates ranging between 50% and 93% [39], thus requiring further investigations, e.g., develop powdered voriconazole in pharmaceutical quality and galenic dosage formulation. Promising efforts include using PLGA (Poly-Lactic-co-Glycol Acid) to achieve a controlled antifungal release pattern. When added to PMMA or ALBC, it is biodegradable and has a release period in vitro ranging from weeks to months [39,40].
Investigations must elaborate on the ideal local antifungal concentration in the context of the standardized measurement of antifungal efficacy.
To effectively control biofilm [12], a high dosage is required. Here, based on the severity of the disease, the risk to the patient may be weighed up. The question of whether high local dosage justifies optional reduced mechanical stability remains to be investigated.

4.4. Limitations

Only one cement was used. It is an in vitro study, and no ethics committee would approve an in vivo study. We believe that an in vitro study can be used to collect data on a very good releasing bone cement. The data can only be reproduced for this one bone cement. Due to different compositions, different results can be expected for other bone cements.

Author Contributions

Conceptualization, methodology, and investigation: K.-D.K. and J.S. The publication is based on the doctoral thesis of J.S. at the Medical University of Graz (Clinical Orthopedic Surgery). The topic “Voriconazole admixed on mechanical properties and efficacy” is a derived and in-depth scientific question. The conception, as well as the supervision of the thesis, was taken over and supervised by K.-D.K. He generated the idea for the present publication. A.T. supervised J.S. at the Centrum for Musculoskeletal Surgery (Centrum für Musculoskeletale Chirurgie) Campus Charite Mitte Berlin as section leader for infectious and septic surgery. The microbiological results were discussed and evaluated with him. Writing—review, B.K.; original draft preparation based on thesis of J.S.; writing—review and editing, K.-D.K.; supervision, K.-D.K. All authors have read and agreed to the published version of the manuscript.

Funding

This research and was funded by Heraeus Medical GmbH. The APC* was funded by Heraeus Medical GmbH.

Institutional Review Board Statement

Not applicable. It is an in vitro study. No animals included.

Informed Consent Statement

Not applicable.

Data Availability Statement

All data are presented in this article. The data are also available on the Medical University of Graz (MUG).

Conflicts of Interest

J.S., A.T. and K.-D.K. declare no conflicts of interest. B.K. is an employee of Heraeus Medical.

References

  1. Patel, R. Periprosthetic Joint Infection. N. Engl. J. Med. 2023, 388, 251–262. [Google Scholar] [CrossRef]
  2. Anagnostakos, K.; Becker, S.L.; Sahan, I. Antifungal-Loaded Acrylic Bone Cement in the Treatment of Periprosthetic Hip and Knee Joint Infections: A Review. Antibiotics 2022, 11, 879. [Google Scholar] [CrossRef] [PubMed]
  3. Adeli, B.; Parvizi, J. Strategies for the prevention of periprosthetic joint infection. J. Bone Jt. Surg. Br. 2012, 94 (Suppl. A11), 42–46. [Google Scholar] [CrossRef]
  4. Azzam, K.; McHale, K.; Austin, M.; Purtill, J.J.; Parvizi, J. Outcome of a second two-stage reimplantation for periprosthetic knee infection. Clin. Orthop. Relat. Res. 2009, 467, 1706–1714. [Google Scholar] [CrossRef] [Green Version]
  5. Kuiper, J.W.P.; van den Bekerom, M.P.J.; van der Stappen, J.; Nolte, P.A.; Colen, S. 2-stage revision recommended for treatment of fungal hip and knee prosthetic joint infections. Acta Orthop. 2013, 84, 517–523. [Google Scholar] [CrossRef] [PubMed]
  6. Hoffmann, R.T.; Jakobs, T.F.; Wallnöfer, A.; Reiser, M.F.; Helmberger, T.K. Perkutane Vertebroplastie: Indikationen, Kontraindikationen und Technik. Radiologe 2003, 43, 709–717. [Google Scholar] [CrossRef] [PubMed]
  7. Jakobs, O.; Schoof, B.; Klatte, T.O.; Schmidl, S.; Fensky, F.; Guenther, D.; Frommelt, L.; Gehrke, T.; Gebauer, M. Fungal periprosthetic joint infection in total knee arthroplasty: A systematic review. Orthop. Rev. 2015, 7, 5623. [Google Scholar] [CrossRef] [Green Version]
  8. Nace, J.; Siddiqi, A.; Talmo, C.T.; Chen, A.F. Diagnosis and Management of Fungal Periprosthetic Joint Infections. J. Am. Acad. Orthop. Surg. 2019, 27, e804–e818. [Google Scholar] [CrossRef]
  9. Enz, A.; Müller, S.; Mittelmeier, W.; Klinder, A. Severe polymicrobial and fungal periprosthetic osteomyelitis persisting after hip disarticulations treated with caspofungin in risk patients: A case series. Ann. Clin. Microbiol. Antimicrob. 2021, 20, 86. [Google Scholar] [CrossRef] [PubMed]
  10. Grzelecki, D.; Grajek, A.; Dudek, P.; Olewnik, Ł.; Zielinska, N.; Fulin, P.; Czubak-Wrzosek, M.; Tyrakowski, M.; Marczak, D.; Kowalczewski, J. Periprosthetic Joint Infections Caused by Candida Species-A Single-Center Experience and Systematic Review of the Literature. J. Fungi 2022, 8, 797. [Google Scholar] [CrossRef]
  11. De Meo, D.; Cera, G.; Ceccarelli, G.; Castagna, V.; Aronica, R.; Pieracci, E.M.; Persiani, P.; Villani, C. Candida fracture-related infection: A systematic review. J. Bone Jt. Infect. 2021, 6, 321–328. [Google Scholar] [CrossRef]
  12. Riaz, T.; Tande, A.J.; Steed, L.L.; Demos, H.A.; Salgado, C.D.; Osmon, D.R.; Marculescu, C.E. Risk Factors for Fungal Prosthetic Joint Infection. J. Bone Jt. Infect. 2020, 5, 76–81. [Google Scholar] [CrossRef] [Green Version]
  13. Miller, R.B.; McLaren, A.C.; Pauken, C.; Clarke, H.D.; McLemore, R. Voriconazole is delivered from antifungal-loaded bone cement. Clin. Orthop. Relat. Res. 2013, 471, 195–200. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  14. Kweon, C.; McLaren, A.C.; Leon, C.; McLemore, R. Amphotericin B delivery from bone cement increases with porosity but strength decreases. Clin. Orthop. Relat. Res. 2011, 469, 3002–3007. [Google Scholar] [CrossRef] [Green Version]
  15. Fusini, F.; Aprato, A.; Massé, A.; Bistolfi, A.; Girardo, M.; Artiaco, S. Candida periprosthetic infection of the hip: A systematic review of surgical treatment and clinical outcomes. Int. Orthop. 2020, 44, 15–22. [Google Scholar] [CrossRef] [PubMed]
  16. Pocket Guide to Diagnosis & Treatment of Periprosthetic Joint Infection (PJI). Available online: http://pro-implant.org/tool/Pocket-guide/1 (accessed on 30 August 2022).
  17. Dennes, E.; Fiorenza, F.; Saint-Marcoux, F.; Megherbi, M.; Dupon, M.; Weinbreck, P. Voriconazole stability in cement spacers. Med. Mal. Infect. 2012, 42, 567–568. [Google Scholar] [CrossRef]
  18. Koutserimpas, C.; Naoum, S.; Alpantaki, K.; Raptis, K.; Dretakis, K.; Vrioni, G.; Samonis, G. Fungal Prosthetic Joint Infection in Revised Knee Arthroplasty: An Orthopaedic Surgeon’s Nightmare. Diagnostics 2022, 12, 1606. [Google Scholar] [CrossRef] [PubMed]
  19. ISO 5833:2002; Implants for Surgery—Acrylic Resin Cement. ISO: Geneva, Switzerland, 2002.
  20. DIN 53435:1983; Testing of Plastics Bending Test and Impact Test on Dynstat Tests Specimens. GlobalSpec: Albany, NY, USA, 1983.
  21. Renz, N.; Cabric, S.; Janz, V.; Trampuz, A. Sonication in the diagnosis of periprosthetic infections: Significance and practical implementation. Orthopaede 2015, 44, 942–945. [Google Scholar] [CrossRef] [PubMed]
  22. Nugent, M.; McLaren, A.; Vernon, B.; McLemore, R. Strength of antimicrobial bone cement decreases with increased poragen fraction. Clin. Orthop. Relat. Res. 2010, 468, 2101–2106. [Google Scholar] [CrossRef] [Green Version]
  23. Dunne, N.J.; Hill, J.; McAfee, P.; Kirkpatrick, R.; Patrick, S.; Tunney, M. Incorporation of large amounts of gentamicin sulphate into acrylic bone cement: Effect on handling and mechanical properties, antibiotic release, and biofilm formation. Proc. Inst. Mech. Eng. H 2008, 222, 355–365. [Google Scholar] [CrossRef]
  24. Von Hertzberg-Boelch, S.P.; Luedemann, M.; Rudert, M.; Steinert, A.F. PMMA Bone Cement: Antibiotic Elution and Mechanical Properties in the Context of Clinical Use. Biomedicines 2022, 10, 1830. [Google Scholar] [CrossRef]
  25. Hansen, E.; Kühn, K.D. (Eds.) Essentials of Cemented Knee Arthroplasty; Springer: Berlin/Heidelberg, Germany, 2022. [Google Scholar]
  26. Sprowson, A.P.; Jensen, C.; Chambers, S.; Parsons, N.R.; Aradhyula, N.M.; Carluke, I.; Inman, D.; Reed, M.R. The use of high-dose dual-impregnated antibiotic-laden cement with hemiarthroplasty for the treatment of a fracture of the hip: The Fractured Hip Infection trial. Bone Jt. J. 2016, 98, 1534–1541. [Google Scholar] [CrossRef]
  27. Kühn, K.D.; Renz, N.; Trampuz, A. Local antibiotic therapy. Unfallchirurg 2017, 120, 561–572. (In German) [Google Scholar] [CrossRef] [Green Version]
  28. Czuban, M.; Wulsten, D.; Wang, L.; Di Luca, M.; Trampuz, A. Release of different amphotericin B formulations from PMMA bone cements and their activity against Candida biofilm. Colloids Surf. B Biointerfaces 2019, 183, 110406. [Google Scholar] [CrossRef]
  29. Hetzmannseder, S.; Chang, Y.; Kittinger, C.; Kühn, K. Properties of Orthopaedic Cements Biomechanically Little Affected by Exceptional Use of Liquid Antibiotics. Orthop. Surg. 2021, 13, 2153–2162. [Google Scholar] [CrossRef]
  30. Chang, Y.H.; Tai, C.L.; Hsu, H.Y.; Hsieh, P.H.; Lee, M.S.; Ueng, S.W. Liquid antibiotics in bone cement: An effective way to improve the efficiency of antibiotic release in antibiotic loaded bone cement. Bone Jt. Res. 2014, 3, 246–251. [Google Scholar] [CrossRef] [Green Version]
  31. Deelstra, J.J.; Neut, D.; Jutte, P.C. Successful treatment of Candida albicans-infected total hip prosthesis with staged procedure using an antifungal-loaded cement spacer. J. Arthroplast. 2013, 28, 374.e5–374.e8. [Google Scholar] [CrossRef] [Green Version]
  32. Beredaki, M.I.; Georgiou, P.C.; Siopi, M.; Kanioura, L.; Arendrup, M.C.; Mouton, J.W.; Meletiadis, J. Voriconazole efficacy against Candida glabrata and Candida krusei: Preclinical data using a validated in vitro pharmacokinetic/pharmacodynamic model. J. Antimicrob. Chemother. 2020, 75, 140–148. [Google Scholar] [CrossRef]
  33. WHO. Fungal Priority Pathogens List to Guide Research, Development and Public Health Action. (Electronic Version); WHO: Geneva, Switzerland, 2022; ISBN 978-92-4-006024-1. [Google Scholar]
  34. Parvizi, J.; Gehrke, T. Proceedings of the Second International Consensus Meeting on Musculoskeletal Infection Consensus of Periprosthetic Joint Infection. Section 3 Treatment. 2013. Available online: https://upload.orthobullets.com/documents/temp/73c7b918-5f54-46d2-87cd-1ab75e3c3a9d50Proceedings%20of%20the%20Second%20International%20Consensus%20Meeting%20on%20Musculoskeletal%20Infection.pdf (accessed on 25 June 2020).
  35. Grimsrud, C.; Raven, R.; Fothergill, A.W.; Kim, H.T. The in vitro elution characteristics of antifungal-loaded PMMA bone cement and calcium sulfate bone substitute. Orthopedics 2011, 34, e378–e381. [Google Scholar] [CrossRef] [Green Version]
  36. Felton, T.; Troke, P.F.; Hope, W.W. Tissue penetration of antifungal agents. Clin. Microbiol. Rev. 2014, 27, 68–88. [Google Scholar] [CrossRef] [Green Version]
  37. Chisari, E.; Lin, F.; Fei, J.; Parvizi, J. Fungal periprosthetic joint infection: Rare but challenging problem. Chin. J. Traumatol. 2022, 25, 63–66. [Google Scholar] [CrossRef]
  38. Sambri, A.; Zunarelli, R.; Fiore, M.; Bortoli, M.; Paolucci, A.; Filippini, M.; Zamparini, E.; Tedeschi, S.; Viale, P.; De Paolis, M. Epidemiology of Fungal Periprosthetic Joint Infection: A Systematic Review of the Literature. Microorganisms 2023, 11, 84. [Google Scholar] [CrossRef]
  39. Kim, J.K.; Lee, D.Y.; Kang, D.W.; Ro, D.H.; Lee, M.C.; Han, H.S. Efficacy of antifungal-impregnated cement spacer against chronic fungal periprosthetic joint infections after total knee arthroplasty. Knee 2018, 25, 631–637. [Google Scholar] [CrossRef]
  40. Gentile, P.; Chiono, V.; Carmagnola, I.; Hatton, P.V. An overview of poly(lactic-co-glycolic) acid (PLGA)-based biomaterials for bone tissue engineering. Int. J. Mol. Sci. 2014, 15, 3640–3659. [Google Scholar] [CrossRef] [Green Version]
Antibiotics 12 00848 g001 550
Figure 1. Samples of green PMMA with admixed voriconazole with white discoloration. (a): PMMA powder with low doses of voriconazole and mortar; (b): PMMA powder with a high dose of voriconazole. (c): PMMA dough with a low dose of voriconazole; (d): PMMA moldings with a high dose of voriconazole. (a–d): Difficulties in admixing voriconazole, especially dose-dependently.
Figure 1. Samples of green PMMA with admixed voriconazole with white discoloration. (a): PMMA powder with low doses of voriconazole and mortar; (b): PMMA powder with a high dose of voriconazole. (c): PMMA dough with a low dose of voriconazole; (d): PMMA moldings with a high dose of voriconazole. (a–d): Difficulties in admixing voriconazole, especially dose-dependently.
Antibiotics 12 00848 g001
Antibiotics 12 00848 g002 550
Figure 2. ISO compressive strength of PMMA cement samples with admixed low (200 mg) and high (600 mg) doses of voriconazole added to PMMA, measured in MPa (limit 70 MPa).The results of the compressive strength test corresponded to the standard specifications of ISO 5833, with one exception, which requires a limit value of at least 70 MPa. The exception was the addition of 10.5 g of voriconazole.
Figure 2. ISO compressive strength of PMMA cement samples with admixed low (200 mg) and high (600 mg) doses of voriconazole added to PMMA, measured in MPa (limit 70 MPa).The results of the compressive strength test corresponded to the standard specifications of ISO 5833, with one exception, which requires a limit value of at least 70 MPa. The exception was the addition of 10.5 g of voriconazole.
Antibiotics 12 00848 g002
Antibiotics 12 00848 g003 550
Figure 3. ISO bending strength of low (200 mg) and high (600 mg) voriconazole admixed with PMMA, measured in MPa (limit 50 MPa).
Figure 3. ISO bending strength of low (200 mg) and high (600 mg) voriconazole admixed with PMMA, measured in MPa (limit 50 MPa).
Antibiotics 12 00848 g003
Antibiotics 12 00848 g004 550
Figure 4. ISO bending modulus admixed low (200 mg) and high (600 mg) voriconazole to PMMA measured in MPa (limit 1800 MPa).
Figure 4. ISO bending modulus admixed low (200 mg) and high (600 mg) voriconazole to PMMA measured in MPa (limit 1800 MPa).
Antibiotics 12 00848 g004
Antibiotics 12 00848 g005 550
Figure 5. DIN impact strength with low (200 mg) and high (600 mg) levels of admixed voriconazole measured in kJ/m2 in comparison to PMMA without the addition of voriconazole.
Figure 5. DIN impact strength with low (200 mg) and high (600 mg) levels of admixed voriconazole measured in kJ/m2 in comparison to PMMA without the addition of voriconazole.
Antibiotics 12 00848 g005
Antibiotics 12 00848 g006 550
Figure 6. Inhibition zone test in mm of low and high concentrations of voriconazole in PMMA over 42 d against Candida albicans.
Figure 6. Inhibition zone test in mm of low and high concentrations of voriconazole in PMMA over 42 d against Candida albicans.
Antibiotics 12 00848 g006
Antibiotics 12 00848 g007 550
Figure 7. Inhibition zone test in mm of low and high concentrations of voriconazole in PMMA over 42 d against Candida glabrata.
Figure 7. Inhibition zone test in mm of low and high concentrations of voriconazole in PMMA over 42 d against Candida glabrata.
Antibiotics 12 00848 g007
Antibiotics 12 00848 g008 550
Figure 8. (a) The prepared moldings were incubated in PBS solution and transferred to a new container with fresh solution at each of the indicated times. The eluates thus obtained were used. (b) Overview of inhibition zone tests of voriconazole containing PMMA specimens with low and high dosages on Sabouraud agar with Candida albicans and Candida glabrata.
Figure 8. (a) The prepared moldings were incubated in PBS solution and transferred to a new container with fresh solution at each of the indicated times. The eluates thus obtained were used. (b) Overview of inhibition zone tests of voriconazole containing PMMA specimens with low and high dosages on Sabouraud agar with Candida albicans and Candida glabrata.
Antibiotics 12 00848 g008
Table
Table 1. Sample composition (g) and designation (mg) as well as powder amount after admixing voriconazole with PMMA powder (g).
Table 1. Sample composition (g) and designation (mg) as well as powder amount after admixing voriconazole with PMMA powder (g).
Pure Voriconazole in mgVoriconazole (Rotexmedica)
Powder for IV Solutions/in g
(including Pharmaceutical Excipients)		Cement Powder Quantity after Adding Low and High Dosages of Voriconazole in g
40.5 g PMMA
reference/sachet		--40.5 g
40.5 g PMMA
reference/sachet		+200 (low dose)+3.544
40.5 g PMMA
reference/sachet		+600 (high dose)+10.551
Table
Table 2. Testing overview: ISO 5833, DIN 53435 Inhibition Zone Test with high (600 mg) and low (200 mg) dosages of voriconazole. The dose–response and mechanical stability of the PMMA–voriconazole mixture were the target criteria. + tested/− not tested.
Table 2. Testing overview: ISO 5833, DIN 53435 Inhibition Zone Test with high (600 mg) and low (200 mg) dosages of voriconazole. The dose–response and mechanical stability of the PMMA–voriconazole mixture were the target criteria. + tested/− not tested.
Test Series OverviewVoriconazole
Low (200 mg)
in PMMA Reference		Voriconazole
High (600 mg)
in PMMA Reference		PMMA Reference
Methods:
ISO compression 70 MPa+++
ISO bending 50 MPa+++
ISO bending modulus
1800 MPa+++
DIN impact strength (Dynstat)+++
Inhibition zone test+++
C. albicans++_
C. glabrata++_
Table
Table 3. Comparison of commercially available voriconazole preparations.
Table 3. Comparison of commercially available voriconazole preparations.
Voriconazole Dosage FormManufacturer/
Product Name		Voriconazole
in mg Active Substance		Excipient in mgTotal WeightThe Active Substance with Respect to Total WeightPublication
Mentioned
Voriconazole Powder for infusionHikma (before Hospira)/
Voriconazole 200 mg Hikma		200 mgEach vial contains 217.6 mg of sodium.
Each vial contains 3200 mg Sulphobutylether beta cyclodextrin sodium (SBECD) (powder for infusion).		3.417 mg5.8% of the total weight is voriconazole.
93.5% of the total weight is SBECD.		Miller et al., 2013 [12]
Voriconazole N/AN/A1000 mgN/AN/AN/ADeelstra et al., 2013 [32]
Voriconazole Powder for infusionRatiopharm/
Voriconazole 200 mg Ratiopharm		200 mgHydroxypropylbetadex:
2500 mg		2.700 mg7.4% of total weight is voriconazole.
92.6% of the total weight is
hydroxypropylbetadex.		SmPC (Feb 2022)
Voriconazole Powder for infusionRotexamedica 200 mgHydroxypropylbetadex (HPBCD): 3300 mg 3.500 mg5.7% of total weight is voriconazole.
94.2% of the total weight is SBECD.		N/A
Voriconazole Powder for infusionPfizer
VFEND 200 mg		200 mgNatrium: 221 mg
Beta-cyclodextrin-sulfobutylether (SBECD): 3200 mg		3.621 mg5.5% of the total weight is voriconazole.
94% of the total weight is SBECD.		SmPC (May 2022)
N/A = not available or no answer.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Krampitz, B.; Steiner, J.; Trampuz, A.; Kühn, K.-D. Voriconazole Admixed with PMMA—Impact on Mechanical Properties and Efficacy. Antibiotics 2023, 12, 848. https://doi.org/10.3390/antibiotics12050848

AMA Style

Krampitz B, Steiner J, Trampuz A, Kühn K-D. Voriconazole Admixed with PMMA—Impact on Mechanical Properties and Efficacy. Antibiotics. 2023; 12(5):848. https://doi.org/10.3390/antibiotics12050848

Chicago/Turabian Style

Krampitz, Barbara, Julia Steiner, Andrej Trampuz, and Klaus-Dieter Kühn. 2023. "Voriconazole Admixed with PMMA—Impact on Mechanical Properties and Efficacy" Antibiotics 12, no. 5: 848. https://doi.org/10.3390/antibiotics12050848

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop